Literature DB >> 1993813

Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses.

S E Wenzel1, J Y Westcott, G L Larsen.   

Abstract

Inflammatory mediators have been implicated in the pathogenesis of human asthma and have been demonstrated to increase in bronchoalveolar lavage fluid during the time of the immediate asthmatic response (IAR) after allergen instillation in the lungs. However, the relationship of these mediators, measured early to the late asthmatic response (LAR), airway reactivity, and clinical asthma, is unknown. In the present study, we evaluated mediator levels in bronchoalveolar lavage fluid before and 5 minutes after allergen challenge from three subject groups: atopic subjects without asthma (N = 7), atopic subjects with asthma and without LAR [-) LAR) (N = 6), and atopic subjects with asthma and with LAR [+) LAR) (N = 6). Subjects with asthma were differentiated into subjects with and without LARs based on at least a 15% decrease in FEV1 between 3 to 8 hours postallergen inhalation. The mediators, prostaglandin D2 thromboxane B2 leukotriene C4 (LTC4), and histamine, were measured both before and after allergen instillation. Baseline prechallenge levels were similar, except in the case of LTC4. LTC4 was detectable at baseline significantly more frequently in the atopic subjects with asthma with and without LAR when these subjects were compared to the atopic subjects without asthma (nine of 12 detectable versus one of seven detectable). In all groups, significant increases in mediator levels were observed in the groups with asthma postallergen challenge, compared to the atopic subjects without asthma. Atopic subjects with asthma and without LAR had significantly higher levels of all four mediators after challenge than atopic subjects with asthma and with LAR and atopic subjects without asthma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993813     DOI: 10.1016/0091-6749(91)90013-e

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  22 in total

Review 1.  Regulation of expression of the 5-lipoxygenase pathway.

Authors:  T D Bigby
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.

Authors:  T C O'Shaughnessy; P Georgiou; K Howland; M Dennis; C H Compton; N C Barnes
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

Review 3.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 4.  Clinical management of asthma in the 1990s. Current therapy and new directions.

Authors:  P Jain; J A Golish
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin.

Authors:  C J Whelan; M Johnson
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

6.  Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction.

Authors:  Anna-Karin Larsson; Magnus Bäck; Jon O Lundberg; Sven-Erik Dahlén
Journal:  Respir Res       Date:  2009-06-04

7.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.

Authors:  S M Nasser; G S Bell; R J Hawksworth; K E Spruce; R MacMillan; A J Williams; T H Lee; J P Arm
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

8.  Anti-asthmatic activities of an ethanol extract of Aster yomena in an ovalbumin-induced murine asthma model.

Authors:  Ji Hyun Sim; Hyun Seung Lee; Sunkyung Lee; Dae Eun Park; Keunhee Oh; Kyung-A Hwang; Hye-Ryun Kang; Sang-Kyu Ye; Hang-Rae Kim
Journal:  J Med Food       Date:  2014-04-16       Impact factor: 2.786

9.  COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity.

Authors:  Dingxin Pan; Kathleen M Buchheit; Sachin K Samuchiwal; Tao Liu; Haley Cirka; Hannah Raff; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-07-12       Impact factor: 10.793

10.  Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.

Authors:  Tao Liu; Yoshihide Kanaoka; Nora A Barrett; Chunli Feng; Denise Garofalo; Juying Lai; Kathleen Buchheit; Neil Bhattacharya; Tanya M Laidlaw; Howard R Katz; Joshua A Boyce
Journal:  J Immunol       Date:  2015-09-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.